[go: up one dir, main page]

MX2019011173A - Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. - Google Patents

Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.

Info

Publication number
MX2019011173A
MX2019011173A MX2019011173A MX2019011173A MX2019011173A MX 2019011173 A MX2019011173 A MX 2019011173A MX 2019011173 A MX2019011173 A MX 2019011173A MX 2019011173 A MX2019011173 A MX 2019011173A MX 2019011173 A MX2019011173 A MX 2019011173A
Authority
MX
Mexico
Prior art keywords
hepatitis
virus infection
silicon
resistance
containing compound
Prior art date
Application number
MX2019011173A
Other languages
English (en)
Inventor
Huang Yu
Xu Hongjiang
Zhang Yinsheng
Liu Baomin
Chen Zhengbang
Gai Kuo
LIU Xushi
Wang Xiaojin
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2019011173A publication Critical patent/MX2019011173A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto que contiene silicio para la resistencia a la infección por virus de la hepatitis c y, en particular, proporciona un compuesto representado por la fórmula I, o una sal farmacéuticamente aceptable, o un tautómero, o un estereoisómero, o un compuesto deuterado del mismo y una mezcla entre ellos, un proceso para la preparación de este, y una composición farmacéutica que comprende el mismo. La presente solicitud también proporciona un uso del compuesto, o una sal farmacéuticamente aceptable, o un tautómero, o un estereoisómero, o un compuesto deuterado del mismo y una mezcla entre ellos, y una composición farmacéutica que comprende el mismo en el tratamiento de la infección por virus de la hepatitis c.
MX2019011173A 2017-03-22 2018-03-22 Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. MX2019011173A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710172925 2017-03-22
CN201710845367 2017-09-19
PCT/CN2018/079965 WO2018171660A1 (zh) 2017-03-22 2018-03-22 用于抗丙型肝炎病毒感染的含硅化合物

Publications (1)

Publication Number Publication Date
MX2019011173A true MX2019011173A (es) 2020-01-09

Family

ID=63585044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011173A MX2019011173A (es) 2017-03-22 2018-03-22 Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.

Country Status (7)

Country Link
US (1) US10766912B2 (es)
EP (1) EP3604295A4 (es)
JP (1) JP2020512331A (es)
CN (1) CN110382487B (es)
BR (1) BR112019019724A2 (es)
MX (1) MX2019011173A (es)
WO (1) WO2018171660A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101558059B (zh) 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2565536T3 (es) 2009-06-11 2016-04-05 Abbvie Bahamas Ltd. Heterociclos trisustituidos como inhibidores de la replicación del virus de la Hepatitis C VHC
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
PE20130062A1 (es) * 2010-03-09 2013-02-28 Merck Sharp & Dohme Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales
JP6162704B2 (ja) * 2011-10-11 2017-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ オキサゾリジノン誘導体のシラアナログ及びその合成
US8927749B2 (en) * 2013-03-07 2015-01-06 Universal Display Corporation Organic electroluminescent materials and devices
WO2016095814A1 (en) * 2014-12-16 2016-06-23 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors and preparation thereof

Also Published As

Publication number Publication date
CN110382487A (zh) 2019-10-25
BR112019019724A2 (pt) 2020-04-14
EP3604295A1 (en) 2020-02-05
US20200017532A1 (en) 2020-01-16
JP2020512331A (ja) 2020-04-23
US10766912B2 (en) 2020-09-08
CN110382487B (zh) 2021-04-02
WO2018171660A1 (zh) 2018-09-27
EP3604295A4 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
MY200608A (en) Hiv inhibitor compounds
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
NZ631754A (en) Amide compounds for the treatment of hiv
NZ703064A (en) Inhibitors of hepatitis c virus
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
AU2018253590A1 (en) Imidazopyridazine compounds
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MY199779A (en) Pyrrolopyrimidine compound and use thereof
PH12017501687A1 (en) Inhibitors of hepatitis c virus polymerase
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2019011173A (es) Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.